MD · Pediatrix Medical Group, Inc.

Pediatrix Medical Group's first quarter 2026 results demonstrated strong performance, with net revenue rising 3.8% year-over-year to $476.2 million, primarily from 2.8% same-unit revenue growth. This was fueled by 4.4% growth from net reimbursement factors, including improved cash collections, higher hospital contract fees, elevated patient acuity in neonatology, and a 45 basis point increase in commercial payor mix, partially offset by 1.6% lower patient volumes. CEO Mark S. Ordan noted results exceeded expectations due to top-line growth, emphasizing priorities on quality support for hospital partners and positioning for new opportunities with robust cash flow. Expenses increased modestly: practice salaries and benefits to $345.7 million from higher clinical salaries, G&A to $60.3 million from incentive compensation, while transformational expenses declined to $4.9 million. Adjusted EBITDA expanded 18% to $58.2 million, reflecting favorable same-unit dynamics and acquisition contributions. GAAP net income of $29.6 million ($0.36/share) and Adjusted EPS of $0.44 both improved significantly. Balance sheet remains solid with $205.8 million cash despite seasonal Q1 cash use of $129.5 million for incentives and benefits, plus $21.5 million in buybacks. Debt stood at $591 million, with lower interest expense from reduced rates and borrowings, and no revolver draw. The company reaffirms full-year Adjusted EBITDA guidance of $280-300 million, signaling confidence amid ongoing revenue cycle transition and practice portfolio management.